Figure 5 Binding characteristics of Lsa33 and Lsa25 proteins to ECM components. (A) Wells were coated with 1 μg of laminin, collagen type I, collagen type IV, cellular fibronectin, plasma fibronectin and the control
proteins gelatin and fetuin. One μg of the recombinant proteins Lsa33 and Lsa25 was added per well and the binding was measured by ELISA. In (A) the protein binding was detected by polyclonal antibodies against each protein, while in (B) protein binding was evaluated with monoclonal anti – polyhistidine serum. Data represent the mean ± the standard deviation from three independent experiments. For statistical analyses, the attachment of recombinant Vemurafenib chemical structure proteins to the ECM components was compared to its binding to gelatin by the two – tailed t test (*P < 0.05). (C) Dose - dependent binding experiments of recombinant proteins with laminin was performed by polyclonal antibodies against each protein; each point was performed check details in triplicate and expressed as the mean absorbance value at 492 nm ± standard error for each point. Gelatin was included
as a negative control. The dissociation constants (KD) are depicted and were calculated based on ELISA data for the recombinant proteins that reached equilibrium. (D) Immobilized laminin was treated with sodium metaperiodate (5 to 100 mM) for 15 min at 4°C in the dark. Mean absorbance values at 492 nm (± the standard deviations of three independent experiments) were compared to those obtained with untreated laminin (0 mM). Interaction of recombinant proteins to serum components Our group has recently reported that leptospires interact with PLG and that several proteins could act as PLG – receptors [17–19, 21]. Protein binding to complement regulators factor H and C4bp have also been shown [31, 32]. Therefore, we set out to evaluate whether the recombinant proteins Lsa33 and Lsa25 were capable of binding human PLG, factor H and C4bp in vitro. The components,
human PLG, factor H and C4bp and the control proteins, gelatin and fetuin, were individually immobilized onto 96 – wells plates followed by incubation with the recombinant leptospiral proteins. The results obtained using polyclonal antibodies against each protein to probe the reactions showed that Lsa33 and Lsa25 Edoxaban interact with C4bp while only Lsa33 appears to bind to PLG (Figure 6A). No reaction was observed with factor H and the control proteins (Figure 6A). Similar results were achieved when binding was performed using monoclonal anti – his tag antibodies (Figure 6B). Both data show that while Lsa33 protein depicted a statistically significant absorption value for the interaction with PLG, the Lsa25 appears to have only a weak or no adherence to this component. These data were further confirmed when the reaction between the recombinant proteins and PLG were assessed on a quantitative basis as illustrated in Figure 6C. Dose – dependent and saturable binding was observed when increasing concentrations (0 to 1.